Reach Out for Our Complimentary Global Biotech Licensing Readiness Assessment In our complimentary one-hour consultation, our team of seasoned professionals will engage in a Q&A session with you. This complimentary offering is designed to provide you with invaluable insights into the international licensing prospects of your product. We will explore your strategic objectives, the strengths […]

Read more

Developing groundbreaking therapies, commercializing products, and/or finding the right partners are all essential activities for successful biotech companies. These tasks can be challenging and hiring an experienced consultant is often the best course of action. Following are the 8 strategic consulting services KYBORA is most often asked to perform. Click here to download the document.

Read more

Sept. 27, 2023 – The Impact of the Inflation Reduction Act (IRA) on Orphan Drugs – ORPHAN Cures Act introduced to boost new rare disease drug development (https://bio.news/health/orphan-cures-act-introduced-to-boost-new-rare-diseasedrug-development/) | The ORPHAN Cures Act, introduced by lawmakers on Sept. 18, 2023, aims to promote the development of new drugs for rare diseases. This legislation responds to […]

Read more

The biotech industry is characterized by intense competition stemming from scientific breakthroughs, innovative therapies, and cutting-edge technologies. Biotech CEOs encounter various challenges when addressing this competitive environment while positioning their companies for success.Click here to download the document.

Read more

In the intricate landscape of biotechnology, the path to introducing innovative products comes with challenges that require strategic expertise. Overcoming market access and reimbursement barriers is crucial for the successful entry and adoption of transformative solutions by Biotech companies in the US market. Click here to download the document:

Read more

Embarking on the global biotech stage, the allure of the Chinese market beckons with undeniable potential. Yet, the path to licensing biotech products in China has its own set of challenges. The intersection of innovation, regulation, culture, and market dynamics creates a complex tapestry that demands careful navigation. Click here to download the document.

Read more

As a Biotech CEO, steering a company through the dynamic landscape of innovation comes with a unique set of challenges, and at the heart of these challenges lies the intricate realm of Intellectual Property (IP). The biotech sector, where breakthrough discoveries can reshape industries and improve lives, demands akeen understanding of how to preserve, protect, […]

Read more

In the dynamic landscape of biotech, securing the right funding is the heartbeat of progress. For innovative startups in this field, the journey from breakthrough idea to market success requires strategic financial support. Here are some prime routes for biotech companies to secure the capital they need. Click here to download the document.

Read more

Biotech research and development serve as the bedrock of groundbreaking advancements, but the journey often demands substantial financial backing. CEOs spearheading these ventures find themselves seeking strategic funding avenues to nurture their companies’ growth and innovation. Licensing emerges as a powerful and versatile approach, presenting an array of opportunities to secure the capital necessary for […]

Read more

SHANGHAI AND PRINCETON, N.J. JUNE 09, 2023KYBORA Life Sciences, a global advisory firm dedicated to facilitating enduring success for life sciences companies, is pleased to announce the appointment of Wang Zhi as Executive Vice President (EVP) and Managing Director of KYBORA Life Sciences (Shanghai) Co., Ltd., effective June 21, 2023.Wang Zhi brings extensive experience and […]

Read more

TYPE & ENTER: